logo
UW researchers figured out how to bypass anti-deepfake markers on AI images

UW researchers figured out how to bypass anti-deepfake markers on AI images

Yahoo23-07-2025
University of Waterloo researchers have built a tool that can quickly remove watermarks identifying content as artificially generated — and they say it proves that global efforts to combat deepfakes are most likely on the wrong track.
Academia and industry have focused on watermarking as the best way to fight deepfakes and "basically abandoned all other approaches," said Andre Kassis, a PhD candidate in computer science who led the research.
At a White House event in 2023, the leading AI companies — including OpenAI, Meta, Google and Amazon — pledged to implement mechanisms such as watermarking to clearly identify AI-generated content.
AI companies' systems embed a watermark, which is a hidden signature or pattern that isn't visible to a person but can be identified by another system, Kassis explained.
He said the research shows the use of watermarks is most likely not a viable shield against the hazards posed by AI content.
"It tells us that the danger of deepfakes is something that we don't even have the tools to start tackling at this point," he said.
The tool developed at the University of Waterloo, called UnMarker, follows other academic research on removing watermarks. That includes work at the University of Maryland, a collaboration between researchers at the University of California and Carnegie Mellon, and work at ETH Zurich.
Kassis said his research goes further than earlier efforts and is the "first to expose a systemic vulnerability that undermines the very premise of watermarking as a defence against deepfakes."
In a follow-up email statement, he said that "what sets UnMarker apart is that it requires no knowledge of the watermarking algorithm, no access to internal parameters, and no interaction with the detector at all."
When tested, the tool worked more than 50 per cent of the time on different AI models, a university press release said.
AI systems can be misused to create deepfakes, spread misinformation and perpetrate scams — creating a need for a reliable way to identify content as AI-generated, Kassis said.
WATCH | :
After AI tools became too advanced for AI detectors to work well, attention turned to watermarking.
The idea is that if we cannot "post facto understand or detect what's real and what's not," it's possible to inject "some kind of hidden signature or some kind of hidden pattern" earlier on, when the content is created, Kassis said.
The European Union's AI Act requires providers of systems that put out large quantities of synthetic content to implement techniques and methods to make AI-generated or manipulated content identifiable, such as watermarks.
In Canada, a voluntary code of conduct launched by the federal government in 2023 requires those behind AI systems to develop and implement "a reliable and freely available method to detect content generated by the system, with a near term focus on audio-visual content (e.g., watermarking)."
Watermark removed 'within 2 minutes max'
Kassis said UnMarker can remove watermarks without knowing anything about the system that generated it, or anything about the watermark itself.
"We can just apply this tool and within two minutes max, it will output an image that is visually identical to the watermark image" which can then be distributed, he said.
"It kind of is ironic that there's billions that are being poured into this technology and then, just with two buttons that you press, you can just get an image that is watermark-free."
Kassis said that while the major AI players are racing to implement watermarking technology, more effort should be put into finding alternative solutions.
Watermarks have "been declared as the de facto standard for future defence against these systems," he said.
"I guess it's a call for everyone to take a step back and then try to think about this problem again."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Aker, Nscale, OpenAI plan $1 billion Norway AI facility
Aker, Nscale, OpenAI plan $1 billion Norway AI facility

Yahoo

time4 minutes ago

  • Yahoo

Aker, Nscale, OpenAI plan $1 billion Norway AI facility

OSLO (Reuters) -Norway's Aker ASA said on Thursday it is partnering with Nscale Global Holdings and OpenAI to build an artificial intelligence facility in northern Norway, aiming to install 100,000 NVIDIA chips by the end of 2026. The partnership, called Stargate Norway, will use 100% renewable energy to power the AI facility, Norwegian conglomerate Aker said in a joint statement with Nscale and OpenAI. Stargate Norway will be owned by a 50/50 joint venture between Nscale and Aker, investing about $1 billion for the initial phase of the project and with the potential to increase the site's capacity tenfold in future phases, they said. The facility, located in a hydropower-rich region of Norway, will be among the first AI gigafactories in Europe, Nscale CEO Josh Payne said in the statement. "Sovereign, scalable and sustainable infrastructure is now essential to remain competitive," he added. Sign in to access your portfolio

China summons chip giant Nvidia over alleged security risks
China summons chip giant Nvidia over alleged security risks

Yahoo

time4 minutes ago

  • Yahoo

China summons chip giant Nvidia over alleged security risks

Chinese internet authorities summoned Nvidia on Thursday to discuss "serious security issues" over some of its artificial intelligence (AI) chips, as the US technology giant finds itself entangled in trade tensions between Beijing and Washington. Nvidia is a world-leading producer of AI semiconductors, but the United States effectively restricts which chips it can export to China on national security grounds. A key issue has been Chinese access to the "H20", a less powerful version of Nvidia's AI processing units that the company developed specifically for export to China. The California-based firm said earlier this month that it would resume H20 sales to China after Washington pledged to remove licensing curbs that had halted exports. But the firm still faces obstacles -- US lawmakers have proposed plans to require Nvidia and other manufacturers of advanced AI chips to include built-in location tracking capabilities. And on Thursday, Beijing's top internet regulator said it had summoned Nvidia representatives to discuss recently discovered "serious security issues" involving the H20. The Cyberspace Administration of China said it had asked Nvidia to "explain the security risks of vulnerabilities and backdoors in its H20 chips sold to China and submit relevant supporting materials". The statement posted on social media noted that, according to US experts, location tracking and remote shutdown technologies for Nvidia chips "are already matured". The announcement marked the latest complication for Nvidia in selling its advanced products in the key Chinese market, where it is in increasingly fierce competition with homegrown technology firms. - Nvidia committed - CEO Jensen Huang said during a closely watched visit to Beijing this month that his firm remained committed to serving local customers. Huang said he had been assured during talks with top Chinese officials during the trip that the country was "open and stable". "They want to know that Nvidia continues to invest here, that we are still doing our best to serve the market here," he said. Nvidia this month became the first company to hit $4 trillion in market value -- a new milestone in Wall Street's bet that AI will transform the global economy. New hurdles to the firm's operation in China come as the country's economy wavers, beset by a years-long property sector crisis and heightened trade headwinds under US President Donald Trump. Chinese President Xi Jinping has called for the country to enhance self-reliance in certain areas deemed vital for national security -- including AI and semiconductors -- as tensions with Washington mount. The country's firms have made great strides in recent years, with Huang praising their "super-fast" innovation during his visit to Beijing this month. ll-pfc/mjw/fox Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale

Yahoo

time4 minutes ago

  • Yahoo

Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale

AI heart failure diagnostics innovator makes it possible to catch deadly heart failure earlier by analyzing the most common heart scan in the world and proactively alerting clinicians FDA-cleared, reimbursed by Medicare, and live in top U.S. hospitals, Ultromics is now scaling nationwide to make early heart failure detection part of routine cardiac care, wherever patients get an echo Ultromics is trained on one of the largest real-world echo datasets globally and validated across 25 peer-reviewed studies, helping close one of medicine's most dangerous diagnostic gaps, where up to 64% of heart failure cases still go undetected OXFORD, England, July 31, 2025 /PRNewswire/ -- Ultromics, a pioneer in AI-driven cardiology solutions, today announced it has raised $55 million in Series C financing. The round was co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises also participated in the round. Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure. The company is now expanding across the U.S. to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders. It's a critical moment for cardiovascular care. Heart failure is rising, costs are mounting and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the U.S. alone, heart failure drives over $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. In fact, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs. Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo® platform supports diagnosis of HFpEF and cardiac amyloidosis. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide. "The reality is, hospitals already have the data, they just haven't had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we're helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses," said Ross Upton, PhD, CEO and Founder, Ultromics. "We've spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis." Ultromics has already analyzed more than 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company's latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions. "Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies," said Alastair Stewart, Head of Investments, Venture Capital, at L&G. "This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year." With growing adoption and partnerships across flagship institutions, including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the Midwest. Its platform is helping hospitals reduce unnecessary tests, streamline workflows and initiate treatment earlier so it's more effective and less expensive. "Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care," said Umur Hursever, Partner at Lightrock. "Ultromics' AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics' mission and growing impact." Ultromics has rapidly expanded its platform capabilities and U.S. market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics' foundation for scaled adoption across U.S. hospitals. "There's a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret," said Victor Westerlind, Managing Director at Allegis Capital. "What's exciting about Ultromics is how they're closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it's a diagnostic win that will help save lives." About Ultromics Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound scan. Ultromics is backed by leading investors and U.S. healthcare systems and is on a mission to transform how heart disease is diagnosed and treated. For more, visit About Lightrock Lightrock is a global investment platform committed to building a sustainable future. Operating across private and public markets, Lightrock manages over $5.5 billion in assets and invests in Europe, North America, Latin America, Asia, and Africa. Lightrock is a certified B Corp with a dedicated team of over 130 professionals working across a network of six offices For more information, visit About L&G Established in 1836, L&G is one of the UK's leading financial services groups and a major global investor, with £1.1 trillion in total assets under management (as at FY24) of which c. 44% (c. £0.5 trillion) is international. We have a highly synergistic business model, which continues to drive strong returns. We are a leading player in Institutional Retirement, in Retail Savings and Protection, and in Asset Management through both public and private markets. Across the Group, we are committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society. About Allegis Capital Allegis Capital is an early-stage venture capital firm partnering with companies that enable digital transformation across the enterprise. The firm supports founders with hands-on guidance, operational expertise, and access to a global network of industry leaders. With a long track record of building market-defining businesses, Allegis backs the teams and platforms reshaping how work gets done. Headquartered in Palo Alto, California, Allegis has been investing in enterprise innovation for over two decades. For more information, visit Photo - - View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store